Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).

被引：0
|
作者：
Ryan, Charles J.
Kim, Won
Buettner, Arden
Britton, Susan Lynne
Lankford, Maria L.
Neely, Doug B.
Green, Mark R.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Xcenda, Tampa, FL USA
[4] Xcenda, Palm Harbor, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Small, E.
    Lance, R.
    Gardner, T. A.
    Karsh, L. I.
    Stubbs, A.
    McCoy, C.
    DeVries, T.
    Redfern, C. H.
    Shore, N. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S683
  • [42] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] Safety of cabazitaxel in elderly patients with metastatic castrate resistant prostate cancer (mCRPC) previously treated with docetaxel therapy.
    Gernone, Angela
    Calderoni, Giuseppe
    Vallarelli, Simona
    Montagna, Elisa
    Pagliarulo, Arcangelo
    Silvestris, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer
    Aggarwal, Rahul
    Halabi, Susan
    Kelly, William Kevin
    George, Daniel
    Mahoney, John F.
    Millard, Frederick
    Stadler, Walter M.
    Morris, Michael J.
    Kantoff, Philip
    Monk, J. Paul
    Carducci, Michael
    Small, Eric J.
    CANCER, 2013, 119 (20) : 3636 - 3643
  • [46] A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
    Kim, Hae Su
    Lee, Ji Yun
    Lee, Su Jin
    Lim, Ho Yeong
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Choi, Han-Yong
    Park, Se Hoon
    BMC UROLOGY, 2017, 17
  • [47] Efficacy and tolerability of Docetaxel in patients with metastatic castrate-resistant prostate cancer older than 70 years compared with younger patients
    Ferreira Maia, M. C. Dias
    Perez Fraile, N. Moreno
    Valente Lage, L.
    Barosso Souza, R.
    Dzik, C.
    Assed Bastos, D.
    Van Vaisberg, V.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S500 - S500
  • [48] Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms
    Chan, Johan
    Ong, Whee Sze
    Ng, Quan Sing
    Toh, Chee-Keong
    Rajasekaran, Tanujaa
    Tan, Wan Ling
    Tan, Hui Shan
    Tan, Min-Han
    Lim, Kiat Hon
    Lee, Yifang
    Wong, Siew Wei
    Wong, Alvin S. C.
    Saad, Marniza Bte
    Ng, Chi-Fai
    Chansriwong, Phichai
    Horie, Shigeo
    Kanesvaran, Ravindran
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [49] A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
    Hae Su Kim
    Ji Yun Lee
    Su Jin Lee
    Ho Yeong Lim
    Hyun Hwan Sung
    Hwang Gyun Jeon
    Byong Chang Jeong
    Seong Il Seo
    Seong Soo Jeon
    Hyun Moo Lee
    Han-Yong Choi
    Se Hoon Park
    BMC Urology, 17
  • [50] Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).
    Yang, Eddy Shih-Hsin
    Leiby, Benjamin
    Sonpavde, Guru P.
    Einstein, David Johnson
    Quinn, Zachary L.
    Szmulewitz, Russell Zelig
    Sartor, A. Oliver
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345